Table 3b.
Results of included studies: peri-implant outcomes
|
Study |
Study Groups |
PI Diagnosis baselinepatient level |
PI Diagnosis final patient level |
PI BoP % baseline |
PI BoP % final |
PI-PD baseline [mm] |
PI-PD final [mm] |
PI bone loss baseline |
PI bone loss final |
Implants with periimplantitis baseline [n] |
Implants with periimplantitis final [n] |
PI keratinised mucosa baseline |
PI keratinised mucosa final |
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
adh: adherence; (ir)reg: (ir)regular; PHP: periodontally healthy patients; PCP: periodontally compromised patients; m: moderate; s: severe; f: female; m: male; n: number; SD: standard deviation; y: year(s); PI: peri-implant; PD: probing depth; PPD: pocket probing depth; BoP: bleeding on probing; CAL: clinical attachment loss. | ||||||||||||||
|
SPIC |
||||||||||||||
|
Costa F.O. et al. (2022) |
Reg |
Healthy: 12 (44.4%)peri-implant mucositis: 20 (74.1%)peri-implantitis: 7 (25.9%) |
Healthy: 17 (63.0%)peri-implant mucositis: 10 (37.0%)peri-implantitis: 4 (14.8%) |
33.3 +/- 25 |
24.2 +/- 14.2 |
% of sites with PI PD > 4mm5.9 +/- 13.6 |
3.3 +/- 8.4 |
individuals with bone lossn=7 |
n=4 |
17 (10.6%) |
6 (4.8%) |
% of sites with KMi ≤1 mm9.0 ± 18.5 |
18.9 ± 21.2 |
|
|
Irreg |
Healthy: 0 (0.0%)peri-implant mucositis: 23 (95.8%)peri-implantitis: 18 (75.0%) |
Healthy: 6 (25.0%)peri-implant mucositis: 17 (70.8%)peri-implantitis: 10 (41.6%) |
62.7 +/- 20.9 |
39.3 +/- 19.8 |
16.7 +/- 27.0 |
10.1 +/- 13.2 |
n=17 |
n=10 |
52 (28.8%) |
24 (22%) |
7.7 ± 15.9 |
21.9 ± 22.7 |
||
|
Roccuzzo A et al. (2022) |
Adh PHP |
patients treated with CIST C/D (10 y)4 (23.5%) |
patients treated with CIST C/D (20 y)5 (29.4%) |
na |
na |
at least 1 site with deepest PD ≥6 mm at 10 years3 (17.7%) |
at least 1 site with deepest PD ≥6 mm at 20 years4 (23.5%) |
na |
na |
na |
na |
na |
na |
|
|
Non-adh PHP |
1 (20%) |
2 (40%) |
2 (40%) |
4 (80%) |
||||||||||
|
Adh mPCP |
9 (52.9%) |
6 (35.3%) |
5 (29.4%) |
6 (35.3%) |
||||||||||
|
Non-adh mPCP |
4 (30.8%) |
8 (61.5%) |
11 (84.6%) |
10 (76.9%) |
||||||||||
|
Adh sPCP |
15 (62.5%) |
16 (66.7%) |
16 (66.7%) |
10 (41.7%) |
||||||||||
|
Non-adh sPCP |
4 (44.4%) |
3 (33.3%) |
9 (100%) |
9 (100%) |